Skip to Content

Zanubrutinib Dosage

Medically reviewed by Drugs.com. Last updated on Feb 28, 2020.

Applies to the following strengths: 80 mg

Usual Adult Dose for Lymphoma

160 mg orally 2 times a day until disease progression or unacceptable toxicity
OR
320 mg orally once a day until disease progression or unacceptable toxicity

Use: For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy

Renal Dose Adjustments

Mild to moderate renal impairment (CrCl 30 mL/min or greater: No adjustment recommended.
Severe renal impairment (CrCl less than 30 mL/min): Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Monitor for adverse reactions.

Liver Dose Adjustments

Mild to moderate hepatic impairment: No adjustment recommended.
Severe hepatic impairment: Reduce dose to 80 mg orally 2 times a day.

Dose Adjustments

DOSE MODIFICATIONS FOR ADVERSE REACTIONS (starting dose of 160 mg 2 times a day OR 320 mg once a day):
FOR:
1) GRADE 3 OR HIGHER NONHEMATOLOGICAL TOXICITIES
OR
2) GRADE 3 FEBRILE NEUTROPENIA; GRADE 3 THROMBOCYTOPENIA WITH SIGNIFICANT BLEEDING
OR
3) GRADE 4 NEUTROPENIA (LASTING MORE THAN 10 CONSECUTIVE DAYS)
OR
4) GRADE 4 THROMBOCYTOPENIA (LASTING MORE THAN 10 CONSECUTIVE DAYS):
Below are dose modifications for the reactions 1 through 4 listed above:
-First Occurrence: Interrupt therapy; when toxicity has resolved to Grade 1 or less or baseline resume at 160 mg 2 times a day or 320 mg once a day
-Second Occurrence: Interrupt therapy; when toxicity has resolved to Grade 1 or less or baseline resume at 80 mg 2 times a day or 160 mg once a day
-Third Occurrence: Interrupt therapy; when toxicity has resolved to Grade 1 or less or baseline resume at 80 mg once a day
-Fourth Occurrence: Discontinue therapy

Asymptomatic lymphocytosis should not be regarded as an adverse reaction, and these patients should continue taking this drug.

Dose Modifications for Concomitant use with CYP450 3A Inhibitors or Inducers:
-Strong CYP450 3A inhibitor: 80 mg orally once a day; interrupt dose as recommended for adverse reactions
-Moderate CYP450 3A inhibitor: 80 mg orally once a day; interrupt dose as recommended for adverse reactions
-Moderate or strong CYP450 3A inducer: Avoid concomitant use.
-After discontinuation of a CYP450 3A inhibitor, resume previous dose of this drug.

Precautions

CONTRAINDICATIONS:
-None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Monitor for adverse reactions.

Other Comments

Administration advice:
-This drug may be taken with or without food.
-Swallow capsules whole with water; do not open, break, or chew.
-If a dose is missed, it should be taken as soon as possible on the same day with a return to the normal schedule the following day.

Storage requirements:
-Store at 20C to 25C (68F to 77F); excursions permitted between 15C to 30C (59F to 86F)

General:

Monitoring:
-Renal function
-Hepatic function
-Cardiac function

Patient advice:
-Read the patient information for this drug each time you have your prescription filled.
-Inform your healthcare provider of all medications you are taking (including
over-the-counter medications, vitamins, and herbal products).

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.